ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years
Multiple myeloma, a complex blood cancer that affects plasma cells, has long posed a formidable challenge in oncology. Over the decades, treatment options have evolved from conventional chemotherapy to proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Despite these advances, long-term survival has remained elusive, especially for patients with relapsed or refractory disease. Historically, most therapies have required continuous treatment and often come with severe side effects and diminishing efficacy over time.
For the full story, please visit Blackdoctor.org
